1. Homepage » 
  2. Settlement

Business location – options for immediate use

Extensive capacity is available for the production of biologic agents, plasmids, and viral vectors.

The Pharma and Life Science Park in Orth is a multi-user campus offering a wide range of development options for biologic agents, CGT, and pDNA, including labs, production facilities, offices, infrastructure, and other build-ready areas.

A) BIOLOGICS

Clinical and launch plants

Clients can lease turnkey production capacity for biologic agents to integrate their business model, processes, and technologies at the site.
A pilot facility with 1.5 kl and a launch facility with 2.5 kl capacity equipped with state-of-the-art Class D and C technology. Cleanrooms can be used alongside labs for MS&T, development, and QC. Operations are conducted in compliance with GxP.
The GxP-compliant operations and a proven track record in the development and delivery of biologic agents allow for a rapid start.

Clinical and launch plants for biologics

B) CELL AND GENE THERAPY

Facilities with a wide range of options

Clients can choose between three different facilities for: 1.) pDNA, 2.) AAV, or 3.) viral vectors (BSL 1 or 2, Class C and D).
With operating licences and a strong track record in the production of AAV subtypes, retroviruses, vaccines or pDNA, the site, with its highly qualified personnel, is ideally suited for cell and gene therapies – from process development to clinical development and launch.

Facilities for cell and gene therapies

C) SUPPORT SERVICES

Labs, offices, infrastructure services

MS&T labs, empty lab space for client QC, BSL 1–2.
Offices are either integrated into production or lab buildings or available separately.
All required infrastructure services (e.g. wide range of black and clean utilities, technical services, infrastructure services) are provided from a single source, allowing tenants at Pharmapark Orth to focus on their core business.

Labor Pharmapark Orth

D) FUTURE TECHNOLOGIES

Outlook and growth

There is potential to expand the current facilities to accommodate technology for multi-stage mRNA production.
Any conceivable modification to existing buildings can be discussed, and full refurbishment or repurposing can be implemented according to client requirements.
Substantial construction areas (87,000 m²) are available on undeveloped land for future growth and expansion.

Zukunftstechnologien Pharmapark Orth
  • All buildings fully qualified and validated
  • Substantial cost and time savings when ramping up operations
  • Rare opportunity to get started immediately with minimal effort

Call

Give us a call: +43 2212 32010 0

 

Contact by email

Contact us by Email